Atria Investments buys $3,158,444 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Atria Investments scooped up 25,575 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment management firm now holds a total of 48,764 shares of AbbVie Inc which is valued at $3,158,444.AbbVie Inc makes up approximately 0.33% of Atria Investments’s portfolio.

Other Hedge Funds, Including , Gw&k Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 25,529 additional shares and now holds a total of 427,352 shares of AbbVie Inc which is valued at $27,679,589. AbbVie Inc makes up approx 0.56% of Gw&k Investment Management’s portfolio.Gulf International Bank (uk) Ltd reduced its stake in ABBV by selling 7,277 shares or 1.47% in the most recent quarter. The Hedge Fund company now holds 487,224 shares of ABBV which is valued at $31,557,498. AbbVie Inc makes up approx 0.52% of Gulf International Bank (uk) Ltd’s portfolio.First National Bank Trust Co Of Newtown reduced its stake in ABBV by selling 500 shares or 2.66% in the most recent quarter. The Hedge Fund company now holds 18,269 shares of ABBV which is valued at $1,172,139. AbbVie Inc makes up approx 0.36% of First National Bank Trust Co Of Newtown’s portfolio.

AbbVie Inc closed down -0.3 points or -0.47% at $63.32 with 88,27,486 shares getting traded on Friday. Post opening the session at $63.82, the shares hit an intraday low of $63.13 and an intraday high of $64.17 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.